All In Biotech

NDA 020498 · Ani Pharms

Casodex

Bicalutamide · Oral · Androgen Receptor Inhibitor

NovelAccelerated approval

Last checked: Nov 19, 2026Latest source record: Nov 1, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Oct 4, 1995

Approved uses

2

Original approval plus efficacy supplements

Registered trials

220

64 Phase 3, 21 recruiting

FAERS reports

15,314

12,703 serious, 2,753 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 23, 2026.

1. INDICATIONS AND USAGE Bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. Bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see Clinical Studies (14.2) ]. Bicalutamide tablets 50 mg is an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. (1) Bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments. (1)

Mechanism: Bicalutamide is a non-steroidal androgen receptor inhibitor. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen. When bicalutamide is combined with LHRH analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected. However, in clinical trials with bicalutamide as a single agent for prostate cancer, rises in serum testosterone and estradiol...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CASODEX · BICALUTAMIDE 50MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Bicalutamide" as an intervention, any sponsor and status, largest first.

All 220 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,344
  • death1,010
  • prostatic specific antigen increased951
  • asthenia819
  • hot flush804
  • prostate cancer757
  • malignant neoplasm progression725
  • drug ineffective613
  • dizziness590
  • nausea569
  • dyspnoea553
  • diarrhoea537

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004224
2005268
2006264
2007235
2008483
2009606
2010505
2011469
2012433
2013560
2014651
2015884
20161,115
20171,170
20181,305
20191,011
2020870
2021890
2022944
2023693
2024631
2025735
2026368

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Casodex (Bicalutamide)

2024 spending

$237K

Beneficiaries

17

50 claims

Per beneficiary

$13,961

$99.64 per unit

View as table
YearSpending
2020$811,316
2021$650,583
2022$420,767
2023$381,414
2024$237,333

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 250 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.